MedBright AI Investments Inc., a prominent investor in healthcare technology (Ticker: MBAI.c or MBAIF for US investors), is expanding its innovative MedMatrix AI platform in collaboration with Rejuvenation, a renowned dermatology group which spans 8 clinics across 3 Canadian provinces known for its advanced care.
This collaboration not only underscores MBAI's capability to form robust partnerships with esteemed medical entities but also highlights the scalability and rapid deployment features of the MedMatrix platform.
With the integration of MedMatrix into its operations, Rejuvenation aims to enhance its capabilities in cosmetic marketing and clinical trial analytics.
The expansion into cosmetic marketing aligns with Rejuvenation's commitment to personalized and advanced care. The new tool will enable Rejuvenation to identify ideal candidates for cosmetic treatments, providing tailored recommendations for enhanced patient experiences and optimal treatment outcomes.
Additionally, MedMatrix's clinical trial recruitment tools will expedite patient eligibility assessments for clinical trials, improving patient access to cutting-edge treatments and streamlining recruitment processes for Rejuvenation's partners, thus contributing to medical research and innovation.
MBAI's strategic focus on healthcare technology investments and its mission to build a synergistic portfolio align seamlessly with Rejuvenation's dedication to excellence.
Together, they aim to leverage AI's potential in healthcare to enhance patient care, foster innovation, and create value for shareholders.
Despite MBAI's market capitalization being below $20 million, the company has achieved significant milestones, securing agreements with 14 clinics in just two months, including Rejuvenation and a clinic group affiliated with the Yale School of Medicine.
Full news here: https://www.medbright.ai/blog-posts/medbright-ais-medmatrix-to-expand-its-ai-offerings-for-cosmetic-marketing-clinical-trial-analytics
Posted on behalf of Medbright AI Investments Inc.